Reinventing the displacement left ventricular assist device in the continuous-flow era: TORVAD, the first toroidal-flow left ventricular assist device

Bartoli, Carlo; Gohean, Jeffrey R.; Smalling, Richard W.

doi:10.21037/acs-2020-cfmcs-19

Cited by 4 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TORVAD produces significantly lower shear stress due to operating at a relatively low speed (60–150 rpm). Furthermore, it provides physiological synchronized pumping through an integrated epicardial sensing lead to analyze heart rate and rhythm, and it senses and adjusts to changes in preload and afterload [ 162 ]. Unlike the HM2, TORVAD caused minimal VWF degradation and hemolysis and did not activate platelets in an ex vivo study, and sheep implanted with TORVAD showed similar findings with no thromboembolism despite lack of anticoagulation [ 162 , 163 ].…”

Section: Future Directionsmentioning

confidence: 99%

“…Furthermore, it provides physiological synchronized pumping through an integrated epicardial sensing lead to analyze heart rate and rhythm, and it senses and adjusts to changes in preload and afterload [ 162 ]. Unlike the HM2, TORVAD caused minimal VWF degradation and hemolysis and did not activate platelets in an ex vivo study, and sheep implanted with TORVAD showed similar findings with no thromboembolism despite lack of anticoagulation [ 162 , 163 ]. While it has not yet been tested in humans, it promises the potential for significant improvements in hemocompatibility.…”

Section: Future Directionsmentioning

confidence: 99%

See 1 more Smart Citation

Vascular Function in Continuous Flow LVADs: Implications for Clinical Practice

et al. 2023

View full text Add to dashboard Cite

Left ventricular assist devices (LVADs) have been increasingly used in patients with advanced heart failure, either as a destination therapy or as a bridge to heart transplant. Continuous flow (CF) LVADs have revolutionized advanced heart failure treatment. However, significant vascular pathology and complications have been linked to their use. While the newer CF-LVAD generations have led to a reduction in some vascular complications such as stroke, no major improvement was noticed in the rate of other vascular complications such as gastrointestinal bleeding. This review attempts to provide a comprehensive summary of the effects of CF-LVAD on vasculature, including pathophysiology, clinical implications, and future directions.

show abstract

Section: Future Directionsmentioning

confidence: 99%

Section: Future Directionsmentioning

confidence: 99%

Vascular Function in Continuous Flow LVADs: Implications for Clinical Practice

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In ex-vivo "mock circulatory" trials, the TORVAD was associated with less blood trauma compared with the HeartMate II and in trials performed with TORVAD in situ for 60 days in sheep, no von Willebrand factor degradation nor significant hemolysis was detected. 71 The CorWave device boasts synchronous pulsatility using an undulating membrane to propel blood from its pump, rather than a rotor. In vitro studies using circulatory models show considerable reductions in hemolysis when compared with the expected degree of hemolysis created for the amount of CO created.…”

Section: Lvadmentioning

confidence: 99%

“…The TORVAD uses a dual piston pump at much lower revolutions-per-minute than its counterparts currently in clinical use, lowering shear stress and blood trauma. In ex-vivo “mock circulatory” trials, the TORVAD was associated with less blood trauma compared with the HeartMate II and in trials performed with TORVAD in situ for 60 days in sheep, no von Willebrand factor degradation nor significant hemolysis was detected 71. The CorWave device boasts synchronous pulsatility using an undulating membrane to propel blood from its pump, rather than a rotor.…”

Section: Future Directions Of Mcsmentioning

confidence: 99%